RWM
ALXN

RBA Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

RBA Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,472
Closed -$4.68M – 24
2021
Q2 		$4.68M Sell
25,472
-221
-0.9% -$37.9K 9.94% 3
2021
Q1 		$3.93M Sell
25,693
-265
-1% -$41K 3.33% 8
2020
Q4 		$4.06M Buy
25,958
+47
+0.2% +$6.04K 2.44% 7
2020
Q3 		$2.96M Buy
25,911
+490
+2% +$52.9K 2% 14
2020
Q2 		$2.85M Buy
25,421
+865
+4% +$91.8K 2.08% 15
2020
Q1 		$2.21M Buy
24,556
+888
+4% +$87.2K 1.91% 16
2019
Q4 		$2.56M Buy
+23,668
New +$2.53M 1.74% 26

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

RBA Wealth Management's ALXN Position: Q3 2021 in Review

RBA Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 25,472 shares — an estimated $4.68M sold.

RBA Wealth Management first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $4.68M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • RBA Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • RBA Wealth Management sold 25,472 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.68M.
  • RBA Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • RBA Wealth Management's Alexion Pharmaceuticals position peaked at $4.68M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on RBA Wealth Management's 13F filing for Q3 2021, filed 15 Nov 2021.